Li Yu

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 688 citations

Phase 1/2, Neuro-oncology, Dose-finding Portion +9

A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation

Jing Xu, Zhongyang Shen, Xinguo Chen et al. · Hepatology · 2007 · 182 citations · Full text

Anti-diabetic effects of luteolin and luteolin-7-<i>O</i>-glucoside on KK-<i>A</i><i>y</i>mice

Yanqing Zang, Kiharu Igarashi, Li Yu · Bioscience Biotechnology and Biochemistry · 2016 · 159 citations · Full text

Anti-diabetic Effects, Glycobiology, Insulin Signaling +17

Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein

Holger Fischer, Mohammed Ullah, Cecile C. de la Cruz et al. · Neuro-Oncology · 2020 · 100 citations · Full text